Study guide
8.4 Drug Administration & Therapy Management
Minnesota MPJE Pharmacy Jurisprudence
Track your progress as you read
Finished sections get a check mark.
1 Introduction & Exam Overview
1.1 About the Minnesota MPJE 1.2 NABP Competency Areas & Weights 1.3 How to Use This Guide & Study Strategy
2 Federal Controlled Substances Foundations
2.1 CSA Schedules I–V & MN Alignment 2.2 DEA Registration, Forms 222/106/41 & Security 2.3 Federal CS Prescription Rules (CII–CV) 2.4 Inventories, Recordkeeping & Theft/Loss
3 Federal Drug Regulation, Privacy & Supply Chain
3.1 FD&C Act, Legend vs OTC, Misbranding & Adulteration 3.2 OBRA '90, Medicaid DUR & Federal Counseling Floor 3.3 HIPAA Privacy for Pharmacy 3.4 DSCSA & Drug Supply Chain Integrity
4 MN Board, Licensure & Eligibility
4.1 Minnesota Board of Pharmacy Authority & Sources of Law 4.2 Pharmacist Licensure by Exam & Score Transfer 4.3 License Transfer (Reciprocity) & Background Checks 4.4 Interns, Preceptors & 1,600-Hour Experience
5 Renewal, CE, PIC & Discipline
5.1 License Renewal & 30-Hour Biennial CE 5.2 Pharmacist-in-Charge Duties 5.3 Discipline & Unprofessional Conduct 5.4 HPSP, Impaired Practitioners & Mandatory Reporting
6 Technicians, Interns & Supervision
6.1 Technician Registration, Training & CE 6.2 Supervision Ratios (Statute 151.102 & Rule 6800.3850) 6.3 Intern Scope, Delegation & Certification of Accuracy
7 Prescription Authority & Validity
7.1 Who May Prescribe in Minnesota 7.2 Prescription Content & Validity Requirements 7.3 Controlled Substance Prescribing (Chapter 152 + Federal) 7.4 Refills, Partial Fills & Quantity Limits
8 Advanced MN Pharmacist Practice
8.1 Collaborative Practice Agreements & Medication Therapy Management 8.2 Pharmacist Prescriptive Authority (Minn. Stat. 151.37) 8.3 Immunizations & Vaccine Administration 8.4 Drug Administration & Therapy Management
9 Counseling, DUR & Patient Safety
9.1 Patient Counseling Requirements (Rule 6800.0910) 9.2 Prospective Drug Utilization Review 9.3 Returning & Reusing Drugs (Rule 6800.2700)
10 MN PMP & Opioid Public-Health Laws
10.1 Minnesota PMP Overview, Reporting & Pharmacist Use 10.2 Naloxone Access, Steve’s Law & Opioid Antagonists 10.3 Legitimate Medical Purpose & Red Flags
11 Dispensing: Transfers, Labels & Substitution
11.1 Prescription Transfers Between Pharmacies 11.2 Labeling & Packaging of Dispensed Drugs 11.3 Generic Substitution & Product Selection 11.4 Emergency Dispensing, OTC/BTC & Pseudoephedrine
12 Pharmacy Operations & Facilities
12.1 Pharmacy Permits, Classifications & Inspections 12.2 Security, Delivery & Work Conditions 12.3 Operational Recordkeeping & Inventories 12.4 Central Fill, Centralized Processing & Automation
13 Compounding & Hazardous Drugs
13.1 Sterile, Nonsterile & Hazardous Compounding 13.2 Minnesota Compounding Rules & Beyond-Use Dates
14 Test-Day Strategy & Final Review
14.1 When Minnesota Law Is Stricter Than Federal Law 14.2 Test-Day Strategy & Common Traps
8.4 Drug Administration & Therapy Management
Key Takeaways Explain This Topic AI
§151.01, subd. 27(4) includes drug administration for first dosage and medical emergencies, and intramuscular and subcutaneous administration under a prescription drug order, plus regimen reviews and related clinical activities.
Clause (5) specifically authorizes IM/SC administration of drugs used to treat mental illnesses either upon a prescriber’s order (with post-administration notice to the prescriber) or under a protocol/CPA with documentation or reporting of changes.
Therapy management—initiation, management, modification, and discontinuation—requires a written protocol or CPA under clause (7), except where a separate statutory prescribing lane (e.g., §151.37) applies.
CLIA-waived testing supports monitoring but does not create freestanding authority to rewrite therapy outside protocol/CPA rules.
Advanced practice acts still sit inside pharmacist professional responsibility: supervision of delegates, documentation, and staying within written plans are exam-critical compliance themes.
Last updated: July 2026
8.4 Drug Administration & Therapy Management
Quick Answer: Minnesota’s practice definition separates (A) administration of drugs from (B) therapy management authority . Under §151.01, subd. 27(4) , pharmacists participate in first-dose and emergency administration and IM/SC administration under a prescription drug order , plus regimen reviews. Clause (5) specially addresses IM/SC drugs used to treat mental illnesses under prescriber order (notify after administration) or protocol/CPA . Clause (7) governs initiation/management/modification/discontinuation of drug therapy under written protocol or CPA . Administration is not automatic license to redesign chronic regimens without a legal hook.
This section stitches together administration vignettes that MPJE items love—long-acting injectables, first-dose observation, emergency epinephrine-type scenarios, and “pharmacist adjusted therapy” fact patterns.
Administration Authorities in Clause (4)
§151.01, subd. 27(4) includes participation in:
- Drug and therapeutic device selection
- Drug administration for first dosage and medical emergencies
- Intramuscular and subcutaneous drug administration under a prescription drug order
- Drug regimen reviews
- Drug or drug-related research
- First dosage and medical emergencies
“First dosage” and “medical emergencies” language supports pharmacist participation when a dose must be given in urgent or initial-dose contexts recognized by the practice definition. Exam stems often involve clinic/pharmacy sites prepared for anaphylaxis response during immunization or injectable therapy. The jurisprudence point is that administration in these contexts is inside the practice of pharmacy , not an unauthorized practice of medicine slogan— provided other legal requirements (order, protocol, training, facility policies, federal rules) are satisfied.
IM/SC under a prescription drug order
For general IM/SC administration under clause (4), the statute ties administration to a prescription drug order . That is different from:
- Vaccine administration under the specialized clause (6) framework
- Mental-illness IM/SC under the specialized clause (5) dual pathway
Pharmacist-prescribed products under §151.37 that may also be administered when that subdivision authorizes administration (notably HIV-prevention drugs under subd. 17)
Order still matters for many injectables: a pharmacist is not free to invent a new IM antibiotic course without a valid order, protocol/CPA, or specific prescribing statute.
Mental-Illness IM/SC — Clause (5)
Clause (5) is a dedicated pathway for drug administration through intramuscular and subcutaneous administration used to treat mental illnesses , permitted under either:
- Path A — Prescriber order + notice
- Administration occurs upon the order of a prescriber , and
- The prescriber is notified after administration is complete
- Path B — Protocol or CPA
Administration proceeds pursuant to a protocol or collaborative practice agreement as defined in subds. 27b and 27c , with initiation/management/modification/administration/discontinuation of drug therapy according to that protocol/CPA between the pharmacist and a dentist, optometrist, physician, PA, podiatrist, veterinarian, or APRN authorized under §148.235
Any changes in drug therapy or medication administration made under the protocol/CPA must be documented in the patient’s medical record or reported to a practitioner responsible for the patient’s care
Exam contrast table:
- Feature Clause (4) general IM/SC Clause (5) mental-illness IM/SC
- Trigger Prescription drug order (among other clause (4) acts) Prescriber order or protocol/CPA
Post-admin notice Not the specialized “notify after complete” rule of clause (5)(i) Notify prescriber after complete when using order path
Therapy changes Separate clause (7) rules if changing therapy Document/report changes under protocol/CPA path
Long-acting injectable antipsychotics are a classic real-world example of why clause (5) exists; answer with the legal pathway , not brand names.
Therapy Management — Clause (7) Revisited in Administration Context
Administration and therapy management overlap when a protocol says “give injection X and adjust schedule Y.” Clause (7) remains the general rule for initiation, management, modification, and discontinuation of drug therapy under written protocol/CPA with authorized practitioners.
Decision tree for stems:
Is the pharmacist only dispensing a practitioner’s Rx? → Ordinary practice rules (validity, DUR, counseling).
Is the pharmacist giving an injection already ordered? → Administration rules (clause (4) or (5) as applicable).
Is the pharmacist changing therapy (dose, agent, stop/start)? → Need protocol/CPA (clause (7)) or a specific §151.37 lane or another statute-specific protocol path (e.g., certain opiate-antagonist protocols).
Did therapy change occur? → Document or report .
CLIA-Waived Testing as a Therapy-Management Tool
Clause (3) again: pharmacists may order/perform CLIA-waived tests, collect specimens, interpret and notify, and refer. They may initiate, modify, or discontinue drug therapy only pursuant to protocol or CPA . Test administration may be delegated to technicians/interns under direct supervision .
Integrated vignette pattern: Pharmacist runs waived INR or glucose-style test → adjusts warfarin/insulin under CPA → documents in record or reports to practitioner. Remove the CPA and the same dose change becomes unauthorized therapy initiation/modification.
Opioid Antagonists and Public-Health Administration Paths
Beyond §151.37, subd. 16 pharmacist prescribing of antagonists for acute overdose, §151.01, subd. 27(11) allows participation in initiation, management, modification, and discontinuation of therapy with opiate antagonists (as defined in §604A.04, subd. 1 ) pursuant to:
A written protocol as allowed under clause (7); or
A written protocol with a community health board medical consultant or a practitioner designated by the commissioner of health , as allowed under §151.37, subd. 13
Administration and access pathways for responders under §151.37, subd. 12 and liability/access concepts under §604A.04 are typically tested with public-health/opioid chapters—but advanced-practice items may blend them. Identify whether the pharmacist is prescribing , protocol-managing , or enabling third-party administration .
Delegation, Supervision, and Professional Judgment
Advanced practice expands what pharmacists may do; it does not erase who must exercise judgment:
Technicians remain non-judgment personnel ( §151.01, subd. 15a ); they may administer tests or vaccines only where statute expressly allows and conditions are met.
Interns may prepare prescriptions for §151.37 products and participate in immunization when trained, but final prescribing approval and core professional determinations stay with the authorized pharmacist.
PIC and supervising pharmacists remain responsible for systems that keep protocol binders current, training documented, and emergency response feasible.
If a stem shows a tech “deciding” to increase an injectable antipsychotic dose without a protocol pathway and without pharmacist judgment, that is unlawful practice structure—not efficient teamwork.
Putting the Advanced-Practice Chapter Together
- Task Primary legal home
- General CPA / protocol therapy management §151.01, subds. 27(7), 27a–27c
- Limited protocol prescribing §151.37, subds. 14–17
- Conditional OUD treatment §151.37, subd. 18
- Vaccines §151.01, subd. 27(6) + vaccine protocol definition
- General IM/SC under Rx order; first dose/emergency §151.01, subd. 27(4)
- Mental-illness IM/SC §151.01, subd. 27(5)
- CLIA-waived testing + linked therapy changes §151.01, subd. 27(3)
- Opiate antagonist therapy protocols §151.01, subd. 27(11); §151.37, subds. 13 & 16
- Study Checklist
Separate administration from therapy change authority.
For mental-illness injectables, recite order + notify or protocol/CPA + document/report .
Require a written protocol/CPA for clause (7) management—not informal habit.
Keep CLIA-waived testing inside monitoring rules; therapy changes need protocol/CPA.
Know how opiate antagonist administration/prescribing paths differ.
Always ask: What written instrument or statute authorizes this act today?
Master these hooks and Area 2 advanced-practice items become pattern recognition rather than guesswork.